We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

17β-HSD

17β-Hydroxysteroid dehydrogenase (17β-HSD) inhibitors in this category mostly target one aldo-keto reductase. Aldo-keto reductase family 1 member C3 (AKR1C3), also called type 5 17β-HSD, reduces androstenedione to testosterone in peripheral tissues. Its close relatives AKR1C1 and AKR1C2 act mainly on other steroids, inactivating progesterone and 5α-dihydrotestosterone. These isoforms share high sequence identity, so selectivity between them is a central question in inhibitor research. AKR1C3-IN-1 and AKR1C2/3-IN-1 address AKR1C3, while AKR1C1-IN-1 is directed at AKR1C1. Stylopine, a protoberberine alkaloid, is also listed as an AKR1C3 inhibitor. AKR1B10-IN-1 targets AKR1B10, a reductase of a neighboring subfamily that is studied in retinoid and lipid metabolism.

1 Item

  • PTOTAC HSD17B13 degrader 1
    Cat. No.
    A69079
    CAS No.
    3046195-01-8

    PTOTAC HSD17B13 degrader 1

    PTOTAC HSD17B13 degrader 1 is a PROTAC designed to selectively target and promote the degradation of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13). This compound consists of a specific ligand for HSD17B13, a linker based on tert-Butyl 5-bromoisoindoline-2-carboxylate, and a ligand for an E3 ubiquitin ligase, enabling effective ubiquitination and subsequent proteasomal degradation of the target protein. PTOTAC HSD17B13 degrader 1 is a valuable tool for studying HSD17B13 functions and has potential applications in therapeutic development and protein regulation research.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...